Financings In Brief: Neurogen
Neurogen: Nets $37.7 mil. (before expenses) from its offering of 2.5 mil. shares of common stock at $16 per share, the Branford, Conn.-based company announces. Psychopharmacological and CNS drug R&D firm plans to use the proceeds to fund R&D, including clinical development of an atypical antipsychotic agent and a diagnostic aid for schizophrenia, both in early stages...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth